Futura Medical plc (FAMDF)
Futura Medical plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Guildford, SU, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $712,597. On trailing twelve-month figures it carries a trailing P/E of -0.31, a net margin of -158.2%. Its beta of 0.00 implies it has historically moved less than the broad market.
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Futura Medical plc is most often compared with the following Healthcare names: